Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Brotchie

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Advances in Therapy|March 10, 2022
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's DiseaseRobert A Hauser, Nir Giladi, Werner Poewe, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 11, 2004
Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's diseaseSusan Fox, Montague Silverdale, Mark Kellett, et al.
Annals of Neurology|March 28, 2012
Dihydropyridine calcium channel blockers and the progression of parkinsonismConnie Marras, Andrea Gruneir, Paula Rochon, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 24, 2004
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropiniroleMark J Millan, Benjamin Di Cara, Michael Hill, et al.
Nature Reviews. Drug Discovery|October 4, 2006
Novel pharmacological targets for the treatment of Parkinson's diseaseAnthony H V Schapira, Erwan Bezard, Jonathan Brotchie, et al.
Experimental Neurology|June 26, 2026
Roles of astrocytic Connexin 43 gap junctional deficit in alpha-synucleinopathy and inflammation relevant to Parkinson'sNataly Hastings, Saifur Rahman, Wei-Li Kuan, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Advances in Therapy|March 10, 2022
P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's DiseaseRobert A Hauser, Nir Giladi, Werner Poewe, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|May 11, 2004
Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's diseaseSusan Fox, Montague Silverdale, Mark Kellett, et al.
Annals of Neurology|March 28, 2012
Dihydropyridine calcium channel blockers and the progression of parkinsonismConnie Marras, Andrea Gruneir, Paula Rochon, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 24, 2004
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropiniroleMark J Millan, Benjamin Di Cara, Michael Hill, et al.
Nature Reviews. Drug Discovery|October 4, 2006
Novel pharmacological targets for the treatment of Parkinson's diseaseAnthony H V Schapira, Erwan Bezard, Jonathan Brotchie, et al.
Experimental Neurology|June 26, 2026
Roles of astrocytic Connexin 43 gap junctional deficit in alpha-synucleinopathy and inflammation relevant to Parkinson'sNataly Hastings, Saifur Rahman, Wei-Li Kuan, et al.
Pageof 2